Introduction {#S1}
============

In the field of stem cells and diabetes, many scientists are actively pursuing the generation of insulin-secreting pancreatic β cells from human pluripotent stem cells (hPSCs) for β cell transplantation/replacement and treatment of diabetes ([@B1]--[@B3]). While insights from rodent pancreas developmental biology has guided the generation of PDX1^+^ pancreatic progenitors from hPSCs, the specific developmental principles thereafter remain murky. Henceforth, research groups have relied upon the transplantation of pancreatic progenitors, derived *in vitro*, into rodents for *in vivo* maturation ([@B4]--[@B6]). However, there has been considerable progress toward the generation of mature and functional human pancreatic β cells *in vitro* in the recent years. These β cells purportedly co-express cardinal β cell markers, such as PDX1, NKX6.1, musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA), prohormone-processing enzymes, insulin, and C-peptide. Importantly, they are also monohormonal and glucose responsive.

Developmental biologists believe that there is much to be learnt from rodent developmental biology to guide hPSC-based generation of clinically useful cell types, such as pancreatic β cells. Owing to such efforts, the progression of definitive endoderm (DE) germ layer to PDX1^+^ pancreatic progenitors has been well-explored. However, the investigations on the later steps of pancreatic endocrine development and β cell maturation have not been quite fruitful. The most substantial advances in stem cell biology have relied upon an arbitrary approach of iterative trial-and-error testing to achieve mature and functional pancreatic β cells *in vitro* ([@B7]). Therefore, several pertinent questions remain: why were we not able to extrapolate rodent developmental principles and apply them on hPSCs to derive mature and functional pancreatic β cells? Are there differences between rodent and human pancreas development that prevent such an application? In this review, we look at signaling pathways that have been activated or repressed in stem cell biology and retrospectively revisit existing knowledge about rodent pancreas biology. Our efforts highlight novel aspects of signaling pathways that can be further investigated in our translational efforts for diabetes.

Inhibition of Transforming Growth Factor-β Signaling in the Later Stages of Pancreatic Differentiation {#S2}
======================================================================================================

The transforming growth factor-β (TGF-β) superfamily of proteins regulates pancreas development and function ([@B8]). TGF-β1, TGF-β2, and TGF-β3 are expressed in pancreatic epithelial cells at E12.5 in mice. Thereafter, they become localized in the acinar cells ([@B9]). TGF-β1 can promote the development of mouse pancreatic β cells from pancreatic buds ([@B10]). Perplexingly, it also indirectly inhibits the formation of mouse pancreatic epithelial cells ([@B11]). In tandem, TGF-β2 has been demonstrated to inhibit *Hnf1*β and *Pdx1* gene expression. Hence, TGF-β can purportedly restrain the specification of pancreatic cell fate ([@B12]). TGF-β signaling effector SMAD3 can bind the *Ins* gene promoter to suppress its expression. In agreement, *Smad3*-deficient islets exhibit an active insulin signaling pathway ([@B13]). Collectively, these evidences suggest the requirement to inhibit TGF-β signaling for the derivation of mature and functional pancreatic β cells (Figure [1](#F1){ref-type="fig"}A).

![**A summary of the pivotal stages of pancreatic differentiation**. **(A)** Mammalian pancreas development based on knowledge from both rodent and human studies. The signaling pathways suggested to be positively regulating the differentiation process are highlighted in green, while those found to be inhibited in order to drive differentiation toward pancreatic lineage are shown in red. **(B)** An *in vitro* pancreatic differentiation timecourse generating β-like cells from hPSCs. The signaling pathways (green) and antioxidants (pink) that are positively regulating the differentiation process at each phase of development are highlighted. Stage-specific signaling pathways that are inhibited to drive differentiation toward pancreatic lineage are shown in red. The decreasing doses of RA used during the differentiation process \[as described by Rezania et al. ([@B6]) and Pagliuca et al. ([@B7])\] are represented by the decreasing shades of green. The differing colors co-existing in an aggregate illustrates the heterogeneity of cells prevalent in such a differentiation scheme. While some of the cells will transit from being endocrine progenitors (light orange) to Pdx1^+^ insulin-producing β-like cells (brown), the end-product will include an assortment of maturing endocrine cell types (represented by orange and light orange).](fendo-06-00194-g001){#F1}

In 2011, Nostro et al. used small molecule SB431542 ([@B14]), an Activin/TGF-β receptor antagonist, in their pancreatic differentiation protocol. SB431542 inhibits activin receptor-like kinases (ALK) 4/5/7 and the downstream TGF-β/Activin/Nodal signaling. SB431542 treatment was demonstrated to increase *INS* gene expression and the development of C-peptide^+^ cells ([@B15]). Similarly, Cho et al. also utilized SB431542, in the presence of retinoic acid (RA), for pancreatic differentiation ([@B16]). Alternatively, Schulz et al. used TGF-βRI kinase inhibitor IV to obtain pancreatic progenitors from CyT49 hPSCs ([@B17]). Rezania et al. identified that the use of 2-(3-\[6-Methylpyridin-2-yl\]-1*H*-pyrazol-4-yl)-1,5-naphthyridine (ALK5iII) can effectively induce the expression of *NGN3*, *NEUROD1*, *INS*, and *GCG* transcripts to promote pancreatic endocrine specification ([@B18]). Rezania et al. further demonstrated that 1 μM ALK5iII is necessary for the induction of NEUROD1^+^ cells, but it suppressed the proportion of NKX6.1^+^ cells ([@B4]), a hallmark of functional β cells ([@B19]). Most recently, Rezania et al. compared the effects of several ALK5 inhibitors at a later phase of differentiation of hPSCs and found that only ALK5iII downregulated *NGN3* while increasing *INS*, *GCG*, and *SST* transcripts ([@B6]). Furthermore, 10 μM ALK5iII induced the expression of nuclear v-maf MAFA transcript, a critical mature β cell transcription factor, in diabetic rodents ([@B20]--[@B22]). Rezania et al. ([@B6]) concluded that ALK5iII was the most effective and specific inhibitor as it inhibited ALK5 but had minimal inhibition of other kinases. Similarly, Pagliuca et al. also employed 10 μM Alk5iII to derive mature and functional human pancreatic β cells from hPSCs ([@B7]) (Figure [1](#F1){ref-type="fig"}B; Table [1](#T1){ref-type="table"}).

###### 

**Summary of some novel signaling pathways perturbed during pancreatic differentiation of hPSCs**.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                             Molecules                                                                            Mechanism                                                                                             Induction of pancreatic lineage markers                                                                  Reference                  Humans   Rodents   
  -------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------- -------- --------- --
  TGF-β inhibition                                                           SB431542                                                                             Inhibits ALK 4/5/7                                                                                    Upregulates *INS* gene expression and C-peptide^+^ cells                                                 Nostro et al. ([@B15])     √                  

  SB431542 + RA                                                              Upregulates *PDX1* gene expression                                                   Cho et al. ([@B16])                                                                                   √                                                                                                                                                      

  TGF-βRI kinase inhibitor IV                                                Induces pancreatic progenitors from hPSCs                                            Schultz et al. ([@B17])                                                                               √                                                                                                                                                      

  1 μM ALK5iII                                                               Inhibits ALK5                                                                        Downregulates *NGN3*. Upregulates *NEUROD*, *INS*, *GCG*, and *SST* transcripts\                      Rezania et al. ([@B4], [@B6], [@B18])                                                                    √                          √                  
                                                                                                                                                                  Induces *Mafa* transcript expression in diabetic rodents                                                                                                                                                                                                     

  10 μM ALK5iII                                                              Pagliuca et al. ([@B7])                                                              √                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                               

  Protein kinase C signaling                                                 300 nM ILV                                                                           Activates PKC\                                                                                        Upregulates gene expression of pancreatic progenitor markers *SOX9*, *PDX1*, *PTF1A*, *HNF6*, *PROX1*\   Chen et al. ([@B26])       √        √         
                                                                                                                                                                  Synergizes with FGF10 signaling                                                                       Upregulates gene expression of endocrine progenitor markers including *NGN3*, *NKX2.2*, and *NKX6.1*                                                   

  500 nM TPB                                                                                                                                                      Upregulates protein expression of FOXA2, PTF1A, HNF6, and NKX6.1                                                                                                                                               √                                             

  14 nM PMA                                                                                                                                                       Downregulates protein expression of endoderm markers CDX2 and AFP                                                                                                                                              √                                             

  50 nM TPB                                                                  Activates PKC                                                                        Upregulates gene expression of pancreatic lineage markers *NGN3*, *NEUROD1*, *PTF1A*, and *NKX6.1*\   Rezania et al. ([@B4])                                                                                   √                                             
                                                                                                                                                                  Downregulates gene expression of intestinal marker *CDX2* and liver marker *ALB*                                                                                                                                                                             

  500 nM PDBu                                                                                                                                                                                                                                                           Pagliuca et al. ([@B7])                                                                                  √                                             

                                                                                                                                                                                                                                                                                                                                                                                                                               

  Low retinoic acid (RA) signaling                                           1--3 μM RA                                                                           Activates RA receptors                                                                                                                                                                                         Various                    √                  

  3 nM TTNPB                                                                 Schulz et al. ([@B17])                                                               √                                                                                                                                                                                                                                                            

  1 μM → 100 nM → 50 nM RA                                                   Rezania et al. ([@B7])                                                               √                                                                                                                                                                                                                                                            

  2 μM → 100 nM → 25 nM RA                                                   Pagliuca et al. ([@B7])                                                              √                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                               

  γ-secretase/Notch inhibitor                                                DAPT                                                                                 Inhibits Notch signaling                                                                              Upregulates *NGN3* mRNA and protein expression in adult islets                                           Dror et al. ([@B36])       √        √         

  Upregulates *NGN3* and *NEUROD1* gene expression                           Rezania et al. ([@B18])                                                              √                                                                                                                                                                                                                                                            

  GSiXX                                                                      Upregulates expression of β cell maturation genes\                                   Rezania et al. ([@B6])                                                                                √                                                                                                                                                      
                                                                             Downregulates expression of pancreatic exocrine marker *PTF1A*                                                                                                                                                                                                                                                                                    

  GSiXX + T3                                                                 Upregulates NKX6.1^+^insulin^+^GCG^-^ β-like cells                                   Rezania et al. ([@B6])                                                                                √                                                                                                                                                      

  1 μM XXI                                                                   Upregulates β cell gene expression                                                   Pagliuca et al. ([@B7])                                                                               √                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                               

  T3                                                                         0.1 μM T3                                                                            Activates MAPK/ERK signaling pathway                                                                  Induces rodent pancreatic β cell proliferation                                                           Kim et al. ([@B42])                 √         

  1 μM T3                                                                    Upregulates expression of *INS* and mature β cell markers                            Rezania et al. ([@B6])                                                                                √                                                                                                                                                      

  Enhances co-expression of NKX6.1 and INS protein                           Pagliuca et al. ([@B7])                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                               

  AXL                                                                        2 μM BGB324 (R428)                                                                   Inhibits AXL                                                                                          Upregulates MAFA protein expression                                                                      Rezania et al. ([@B6])     √                  

  GAS6                                                                       Activates AXL                                                                        Downregulates *Mafa* gene expression                                                                  Haase et al. ([@B48])                                                                                                               √                  

                                                                                                                                                                                                                                                                                                                                                                                                                               

  Antioxidants                                                               GPx-1                                                                                Antioxidants                                                                                          Maintains protein expression of nuclear MAFA in diabetic rodents                                         Harmon et al. ([@B22])              √         

  NAC                                                                        Harmon et al. ([@B21])                                                               √                                                                                                                                                                                                                                                            

  Ebselen                                                                    Mahadevan et al. ([@B20])                                                            √                                                                                                                                                                                                                                                            

  1--2 mM NAC                                                                Upregulates nuclear MAFA protein expression                                          Rezania et al. ([@B6])                                                                                √                                                                                                                                                      

  0.25 mM vitamin C                                                          Generates mature and functional human pancreatic β cells                             Pagliuca et al. ([@B7])                                                                               √                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                               

  Betacellulin                                                               BTC                                                                                  Binds to ErbB-1 and ErbB-4 receptors to initiate PI3K/Akt, MAPK, STAT, and mTOR signaling pathways    Upregulates insulin secretion                                                                            Dahlhoff et al. ([@B65])            √         

  Upregulates mRNA and protein expression of IRS-2                           Oh et al. ([@B68])                                                                   √                                                                                                                                                                                                                                                            

  Induces *Pax4* gene expression in rat islets                               Brun et al. ([@B70])                                                                 √                                                                                                                                                                                                                                                            

  Sustains *PDX1* expression and induces β cell differentiation from hESCs   Cho et al. ([@B71])                                                                  √                                                                                                                                                                                                                                                            

  10 ng/ml BTC                                                               Upregulates *Pdx1* gene expression and insulin production\                           Thowfeequ et al. ([@B72])                                                                                                                                                                                      √                                             
                                                                             Downregulates amylase and glucagon production in mouse embryonic pancreas explants                                                                                                                                                                                                                                                                

  20 ng/ml BTC                                                               Induces pancreatic differentiation                                                   Pagliuca et al. ([@B7])                                                                               √                                                                                                                                                      

  50 ng/ml EGF                                                               Preserves cell mass                                                                  Schulz et al. ([@B17])                                                                                √                                                                                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*BTC, Betacellulin; DAPT, *N*-\[*N*-(3,5-difluorophenacetyl-[l]{.smallcaps}-alanyl)\]-*S*-phenylglycine t-butyl ester; GPx-1, glutathione peroxidase-1; GSiXX, γ secretase inhibitor XX; ILV, (−)-indolactam V; NAC, *N*-acetylcysteine; PDBu, phorbol 12,13-dibutyrate; PMA, phorbol-12-myristate-13-acetate; T3, [l]{.smallcaps}-3,3′,5-Triiodothyronine; TPB, \[(2S,5S)-(E,E)-8-(5-(4-(trifluoromethyl)phenyl)-2,4-pentadienoylamino) benzolactam\]*.

Overall, the inhibition of ALK5/TGF-βRI with ALK5iII appears to be more desirable as compared to the general inhibition of TGF-β signaling via the use of SB431542. Further studies are certainly required to investigate the intricacies of TGF-β signaling during pancreas development and β cell maturation.

Protein Kinase C Signaling Enhancement {#S3}
======================================

Protein kinase C (PKC) is a family of serine/threonine kinases that are involved in diverse cellular processes, including survival, apoptosis, cell cycle regulation, proliferation, migration, and differentiation ([@B23]). In maturing neonatal rat islets, PKCα was only found in β cells, PKCγ in α cells, and PKCϵ in δ cells ([@B24]). This differential expression of PKC isoenzymes ([@B25]) hints that PKC signaling may play a role in the functional maturation of pancreatic endocrine progenitors (Figure [1](#F1){ref-type="fig"}A).

Chen et al. ([@B26]) was the first to demonstrate that 300 nM (−)-indolactam V (ILV) or PKC agonists {500 nM \[(2*S*,5*S*)-(*E*,*E*)-8-(5-(4-(trifluoromethyl)phenyl)-2,4-pentadienoylamino) benzolactam (TPB)\] or 14 nM phorbol-12-myristate-13-acetate (PMA)} can efficiently increase the formation of PDX1^+^ pancreatic progenitors from hPSCs via the activation of PKC signaling. ILV treatment resulted in an increased gene expression of several pancreatic progenitor markers, including *SOX9*, *PDX1*, *PTF1A*, *HNF6*, and *PROX1*, and endocrine progenitor markers, including *NGN3*, *NKX2.2*, and *NKX6.1*. The protein expression of pancreatic progenitor markers FOXA2, PTF1A, HNF6, and NKX6.1 were increased, whereas the expression of intestinal marker CDX2 and liver marker AFP were suppressed ([@B26]). In addition, they also found that ILV and PKC agonists, TPB or PMA, can synergize with FGF10 signaling to promote the proliferation of PDX1^+^ cells derived from hPSCs. Interestingly, ILV treatment also works on mouse embryonic stem cells, suggesting a conservation of signaling pathway in both mouse and human cells ([@B26]) (Table [1](#T1){ref-type="table"}).

Subsequently, Rezania et al. ([@B4]) employed two PKC activators in the mid-late stage of hPSC differentiation; 50 nM TPB (safer profile) and phorbol 12,13-dibutyrate (PDBu) ([@B27]), demonstrating that the activation of PKC signaling induces the gene expression of pancreatic lineage markers *PTF1A*, *NGN3*, *NEUROD1*, and *NKX6.1* while suppressing the expression of intestinal (*CDX2*) and liver (*ALB*) markers ([@B4]). This demonstrated that PKC signaling enriches the development of pancreatic progenitors while inhibiting intestinal and hepatic lineages. Similarly, Pagliuca et al. used 500 nM PDBu in their pancreatic differentiation protocol ([@B7]) (Figure [1](#F1){ref-type="fig"}B; Table [1](#T1){ref-type="table"}). Although these data are encouraging, more studies remain to be done to thoroughly clarify the role of PKC signaling and the specific mechanisms in the maturation of pancreatic endocrine progenitors.

Lower Level of Retinoic Acid Signaling as Pancreatic Differentiation Progresses {#S4}
===============================================================================

It is well-established that RA signaling plays critical roles in the early and late stages of pancreas development ([@B28]). RA is a lipid-soluble vitamin A derivative synthesized from the oxidation of retinaldehyde via enzymes retinaldehyde dehydrogenase 1 (RALDH1), RALDH2, and RALDH3. RA produced at the splanchnic lateral plate mesoderm and Raldh2 expressed in the dorsal pancreatic mesenchyme promote Pdx1 induction in the dorsal foregut endoderm (Figure [1](#F1){ref-type="fig"}A). Raldh2 mutant mice exhibit dorsal pancreatic bud agenesis ([@B29]) as they fail to form pancreatic progenitors, indicated by the loss of Pdx1, Prox1, altered Isl1, and reduced Hlxb9 expression ([@B29], [@B30]).

Many existing protocols differentiating hPSCs into pancreatic cells utilize 1--3 μM RA. As an alternative, Schulz et al. replaced RA with 3 nM TTNPB/arotinoid acid -- a more stable retinoid analog that can selectively activate RA receptors (RARs) ([@B17]). Interestingly, Rezania et al. started out using 1 μM RA during the early posterior foregut differentiation, subsequently reducing to 100 nM RA during pancreatic endoderm phase and further reducing to 50 nM during the pancreatic endocrine phase ([@B6]). Pagliuca et al. also reported a similar pancreatic differentiation protocol in which a decreasing dose of RA was used, starting with 2 μM followed by 100 nM RA at later stages, which was eventually reduced to 25 nM ([@B7]) (Figure [1](#F1){ref-type="fig"}B; Table [1](#T1){ref-type="table"}).

While it is widely accepted that RA is crucial for pancreatic specification, using progressively lower doses of RA as practiced by Rezania et al. ([@B6]) and Pagliuca et al. ([@B7]) raises questions about the importance of RA concentrations during pancreas development both *in vitro* and *in vivo*. RA signals by binding RARs and retinoid X receptors (RXRs); so it is postulated that a decrease in RA signaling may be more conducive for subsequent pancreatic endocrine specification since retinoid receptors are upregulated in the pancreatic exocrine ([@B31]). However, given the lack of understanding in this regard, the significance of the dose of RA during human pancreas development warrants further studies.

Inhibiting γ-Secretase/Notch for Accelerated Pancreatic Endocrine Differentiation {#S5}
=================================================================================

Notch signaling is essential for the proper development of pancreatic endocrine progenitors as it regulates their decision between differentiation and proliferation ([@B32]). The reduction of Notch signaling is known to promote accelerated pancreatic endocrine differentiation ([@B33]). Similarly, the inhibition of Notch signaling via γ-secretase (an intra-membrane protease) inhibitor can downregulate the expression of Notch target Hes-1, an inhibitor of pro-endocrine gene Ngn3 ([@B34]) (Figure [1](#F1){ref-type="fig"}A). Conversely, the activation of Notch in PDX1^+^ pancreatic progenitors prevents pancreatic differentiation ([@B35]).

*N*-\[*N*-(3,5-difluorophenacetyl-[l]{.smallcaps}-alanyl)\]-*S*-phenylglycine t-butyl ester (DAPT) is a commonly used γ-secretase inhibitor with an IC50 in the nM range. The inhibition of Notch signaling with DAPT can increase Ngn3 mRNA and protein expression in adult islets ([@B36]). Likewise, DAPT increases *NGN3* and *NEUROD1* gene expression in hPSC-derived pancreatic progenitors ([@B18]). In recent protocols developed by Pagliuca et al. ([@B7]) and Rezania et al. ([@B6]), other γ-secretase inhibitors have been employed to retard Notch signaling. Rezania et al. used γ-secretase inhibitor XX (GSiXX) that has an IC50 in the low nM range. They showed that GSiXX can induce the expression of β cell maturation genes but inhibit the expression of *PTF1A*, a marker of pancreatic exocrine lineage ([@B6]). GSiXX can also act in concert with triiodothyronine (T3) to increase the percentage of NKX6.1^+^INS^+^GCG^−^ β-like cells ([@B6]). Alternatively, Pagliuca et al. employed the use of XXI at 1 μM ([@B7]), which has an IC50 in the picomolar range, and demonstrated that XXI worked with other factors to improve β cell gene expression (Figure [1](#F1){ref-type="fig"}B; Table [1](#T1){ref-type="table"}). However, it remains unclear whether there are differences between DAPT, GSIXX, or XXI in the induction or suppression of key pancreatic transcription factors for the eventual promotion of pancreatic β cell formation.

Triiodothyronine Could Promote Pancreatic β Cell Maturation {#S6}
===========================================================

Studies in the 1980s suggest that thyroid hormones regulate insulin secretion, possibly via control over glucose oxidation and calcium uptake rates ([@B37]). T3, a thyroid hormone, can potentiate insulin signaling and increase insulin synthesis in diabetic rodents ([@B38]), in rodent islets ([@B39]), and in a rodent pancreatic β cell line ([@B40]) (Figure [1](#F1){ref-type="fig"}A). Mechanistically, T3 phosphorylates and activates AKT in pancreatic β cells, improving their survival ([@B39], [@B41]); 0.1 μM of T3 can increase rodent pancreatic β cell proliferation via the MAPK/extracellular signal-regulated kinase (ERK) signaling pathway ([@B42]). Interestingly, T3 apparently induces the transdifferentiation of human pancreatic ductal cell line (hPANC-1) into β-like cells, with an increased expression of *INS* transcripts ([@B43]). T3 can also increase both the mRNA expression of pro-endocrine gene Ngn3 and the number of β cells, indirectly inducing endocrine differentiation from exocrine cells; possibly via Akt signaling ([@B44]).

Of late, T3 has been shown to promote pancreatic β cell maturation and proliferation in rats ([@B45]). Based on these findings, Rezania et al. went on to demonstrate that 1 μM of T3 can actually induce the expression of *INS* and mature β cell markers, and enhance the co-expression of NKX6.1 and INSULIN protein ([@B6]). Similarly, Pagliuca et al. employed the same dose of 1 μM T3 in the later stages of their pancreatic differentiation protocol to generate human pancreatic β cells from hPSCs ([@B7]) (Figure [1](#F1){ref-type="fig"}B; Table [1](#T1){ref-type="table"}). While the biology and role of T3 in pancreatic β cell maturation remains to be explored further, its inclusion in pancreatic differentiation protocols appears to serve a positive function.

Inhibition of Tyrosine Kinase Receptor Axl Induces Mature Pancreatic β Cell Marker (Mafa) Expression {#S7}
====================================================================================================

AXL is a member of the Tyro3-Axl-Mer (TAM) trans-membrane receptor tyrosine kinase (RTK) family that plays an important role in essential cellular processes, such as cell survival, growth, proliferation, and differentiation. Its ligand, growth arrest specific 6 (Gas6), binds AXL to activate downstream signaling, including the phosphoinositide 3-kinase (PI3K), ERK, and signal transducer and activator of transcription 3 (STAT3) signaling ([@B46]). Interestingly, Rezania et al. performed small molecule and growth factor library screening to identify compounds that can induce mature β cell marker MAFA from hPSC-derived pancreatic progenitors and found that 2 μM BGB324 (R428), an inhibitor of AXL, can induce MAFA protein expression ([@B6]) (Figure [1](#F1){ref-type="fig"}B; Table [1](#T1){ref-type="table"}). However, there is little information linking AXL to pancreas development and β cell maturation.

In 1999, Augustine et al. reported that the overexpression of AXL results in diabetes in mice. Furthermore, the administration of exogenous Gas6 exacerbated the condition ([@B47]). Haase et al. recently confirmed that GAS6 is expressed in pancreatic tissues and found that GAS6 reduced *Mafa* gene expression in rodents ([@B48]), likely due to the activation of AXL (Figure [1](#F1){ref-type="fig"}A). This corresponds with the increase in MAFA expression observed by Rezania et al. after the inhibition of AXL signaling ([@B6]). While there seems to be a *bona fide* association between AXL signaling and pancreas development, the cellular mechanism(s) remain a mystery.

Antioxidants may Benefit Pancreatic Differentiation {#S8}
===================================================

Excessive levels of reactive oxygen species (ROS) have been implicated in glucotoxicity-induced pancreatic β cell destruction and dysfunction. In this regard, antioxidants play important defensive roles against ROS. In the endocrine pancreas, the antioxidant vitamin C is known to be an effective co-factor for the peptidyl α-amidation of several biologically active peptides and is necessary for optimal insulin secretion from pancreatic β cells (Figure [1](#F1){ref-type="fig"}A). In fact, high concentrations of ascorbic acid (vitamin C) were found in neonatal rat endocrine pancreas ([@B49]). Mechanistic studies involving other antioxidants, such as glutathione peroxidase-1 (GPx-1), *N*-acetylcysteine (NAC), and ebselen, were reported to maintain the protein expression of mature β cell marker MAFA ([@B20]--[@B22]) (Table [1](#T1){ref-type="table"}).

Interestingly, Rezania et al. used 1--2 mM NAC during their pancreatic differentiation and found that it also increased nuclear MAFA protein expression ([@B6]). However, this was not replicated with another antioxidant, vitamin E. Pagliuca et al. also relied upon the use of 0.25 mM of vitamin C throughout S1--S5 phase of their pancreatic differentiation protocol to generate mature and functional human pancreatic β cells ([@B7]) (Figure [1](#F1){ref-type="fig"}B; Table [1](#T1){ref-type="table"}). While the metabolism of vitamins C and E are altered before the onset of diabetes in rats, their contribution to the pancreas is unclear ([@B50]). Antioxidant treatments may preserve β cell function, exerting positive effects in diabetes ([@B51]), but their role in pancreas development and β cell maturation certainly remains elusive.

Betacellulin Directs a Pancreatic β Cell Fate {#S9}
=============================================

Betacellulin (BTC) is a member of the epidermal growth factor (EGF) family that plays a role in the differentiation of pancreatic β cells ([@B52]) (Figure [1](#F1){ref-type="fig"}A). It is largely expressed in the liver, kidney, small intestine, and pancreas ([@B53]), and is specifically expressed in 9- to 24-week-old human fetal pancreas ([@B54]). BTC binds to ErbB-1 and ErbB-4 receptors ([@B55]) to initiate downstream signaling pathways involving PI3K/Akt, MAPK, STAT, and mTOR signaling pathways ([@B56]).

Betacellulin appears to direct a pancreatic β cell fate. It can convert exocrine cells ([@B57]) and α cells ([@B58]) into insulin-secreting cells. It can also induce β cell neogenesis from ductal cells in diabetic mice ([@B59]). Li et al. demonstrated that exogenous BTC can promote β cell regeneration in 90% pancreatectomized rats ([@B60]) and convert δ to β cells in STZ-induced diabetic mice ([@B61]). Also, Yamamoto et al. observed that long-term administration of BTC reverses STZ-induced hyperglycemia in mice ([@B62]). Surprisingly, the loss of BTC in mice yielded no overt defect ([@B63]) despite their active roles in the pancreas. This could be explained by compensatory effects exhibited by the other EGFR ligands ([@B64]). The overexpression of BTC in transgenic islets does not affect islet structure, endocrine cell ratio, or β cell mass but enhances glucose-stimulated insulin secretion ([@B65]). However, ubiquitous overexpression of BTC in mice results in various pathologies ([@B66]). Intriguingly, gene variants and polymorphisms in the *BTC* gene have also been found to be associated with types 1 and 2 diabetes ([@B54], [@B67]).

The induction of β cell development/differentiation by BTC ([@B52]) could be an outcome of the downstream increase in insulin receptor substrate-2 (IRS-2) expression ([@B68]), an important mediator of β cell function ([@B69]). BTC can induce *Pax4* gene expression in rat islets, promoting β cell functionality ([@B70]). It can also sustain *PDX1* expression and induce β cell differentiation from hPSCs ([@B71]). Ten ng/ml BTC are sufficient to increase *Pdx1* gene expression, insulin production, and to inhibit amylase and glucagon production in mouse embryonic pancreas explants ([@B72]). Lately, Pagliuca et al. employed 20 ng/ml BTC in the later stages of their pancreatic differentiation protocol ([@B7]). Similarly, 50 ng/ml EGF was added to preserve cell mass ([@B17]) (Figure [1](#F1){ref-type="fig"}B; Table [1](#T1){ref-type="table"}). These data strongly indicate that BTC and/or other EGF ligands are of importance in pancreas development and β cell maturation. Nonetheless, more detailed molecular mechanisms remain to be uncovered.

Concluding Remarks {#S10}
==================

Relating to the current most advanced human pancreatic β cell differentiation protocols, the biological mechanisms involved in the later stages of β cell development and maturation still remain elusive. The fact that the postnatal stage in rodents is grossly equivalent to the third trimester in human pancreas development ([@B73]) invites new approaches to study this aspect of β cell biology. In this review, we revisited some of the least-understood developmental signaling pathways in rodent pancreas biology. Our efforts unraveled interesting aspects of these signaling pathways that demand to be thoroughly elucidated at the mechanistic level. Future studies should seek to highlight how immature β cells transit into mature and functional β cells. This would certainly advance our knowledge of human pancreas developmental biology and boost translational efforts in the use of stem cells for diabetes treatment.
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